wegovy glp 1 agonist Wegovy® is now accessible to eligible Medicare beneficiaries living with obesity through Medicare GLP-1 Bridge New Weight Loss Drugs: GLP-1

These medications' effects on gastric function create important considerations for patients scheduled to undergo colonoscopy or other endoscopic procedures

The same principles of placement, hold time, empty stomach, and post-dose fasting apply equally

conversely, Tirzepatide had the slowest onset (19.5 weeks), taking 46 weeks to reach its efficacy plateau

Bariatric surgery volumes are declining for the first time in recorded history as GLP-1 pharmacotherapy outcomes approach surgical efficacy thresholds

Perhaps the better approach is to use an algorithm that includes gastric ultrasound, rapid sequence induction if GA is required, and greater use of clinical signs

This is not universal GLP-1 coverage, and patients should not assume every medication, dose, plan, or diagnosis will qualify